Today: 9 June 2026
Browse Category

NYSE:CCJ 28 October 2025 - 31 May 2026

Cameco Stock Is Back in Focus After a Mine Restart — What Investors Watch Next

Cameco Stock Is Back in Focus After a Mine Restart — What Investors Watch Next

Cameco shares closed Friday at C$154.91 on the TSX, up 7.1% for the week after full production resumed at McArthur River and Key Lake following flood-related disruptions. The company kept its 2026 uranium output guidance unchanged at 19.5–21.5 million pounds. CIBC and National Bank of Canada maintained “Outperform” ratings. Cameco reported Q1 net earnings of C$131 million earlier in May.
31 May 2026
···
Cameco Trades Higher in Toronto as U.S. Markets Closed; Uranium Trade Eyes What’s Next

Cameco Trades Higher in Toronto as U.S. Markets Closed; Uranium Trade Eyes What’s Next

Cameco shares rose C$2.33 to C$146.96 on the Toronto Stock Exchange Monday, while U.S. trading paused for Memorial Day. The company posted C$131 million in Q1 net earnings and reaffirmed its 2026 uranium production forecast. Cameco’s C$2.6 billion uranium supply contract with India runs from 2027 to 2035. The spot uranium price held at $84.70 per pound on May 22.
25 May 2026
···
Cameco Corporation Earnings Countdown: The Uranium Stock Test Investors Are Watching

Cameco Corporation Earnings Countdown: The Uranium Stock Test Investors Are Watching

Cameco shares closed lower Friday, with NYSE-listed CCJ at $120.60 and TSX-listed CCO at C$163.66. The uranium supplier reports first-quarter results before markets open May 5, followed by an executive call at 8 a.m. Eastern. Investors are watching uranium prices, delivery timing, and Cameco’s 49% stake in Westinghouse. The company’s annual meeting is set for May 7.
3 May 2026
····
Cameco Corporation Stock Slips Before Q1 Results — Why Uranium Investors Are Watching May 5

Cameco Corporation Stock Slips Before Q1 Results — Why Uranium Investors Are Watching May 5

Cameco’s U.S.-listed shares closed Friday at $122.15, down 1.4% ahead of its first-quarter results due May 5. Uranium prices held at $86.80 a pound, up 30% from a year earlier. Analysts maintain a “Moderate Buy” on the stock, with a C$174.85 target for Toronto-listed shares. Cameco delivered 33 million pounds of uranium in 2025 and holds long-term contracts for about 230 million pounds.
26 April 2026
···
Cameco Corporation Stock Faces a May 5 Test After Friday’s Uranium Pullback

Cameco Corporation Stock Faces a May 5 Test After Friday’s Uranium Pullback

Cameco’s U.S.-listed shares fell $1.70 to $122.15 Friday, while Toronto shares dropped C$2.45 to C$167.02. The uranium producer will report first-quarter results before markets open May 5, with an executive call set for 8:00 a.m. Eastern. Other uranium stocks, including NexGen Energy and Uranium Energy, also declined in U.S. trading. Cameco produced 21 million pounds of uranium in 2025 and delivered 33 million pounds.
25 April 2026
··
Oklo Stock Surges as White House Space Nuclear Plan and Board Overhaul Lift Reactor Shares

Oklo Stock Surges as White House Space Nuclear Plan and Board Overhaul Lift Reactor Shares

Oklo shares climbed 8.5% to $69.69 by midday Friday after the company overhauled its board and the White House called for faster space-reactor development. The board expanded to 11, adding Mark Peters and David Christian. NuScale Power and BWX Technologies also rose. Oklo’s market value hit $16.5 billion, despite no 2025 revenue and a $105.7 million net loss.
17 April 2026
····
Energy Fuels stock jumps 13% as Trump’s ‘Project Vault’ fuels rare earth, uranium rally

Energy Fuels stock jumps 13% as Trump’s ‘Project Vault’ fuels rare earth, uranium rally

Energy Fuels Inc. shares jumped 13.4% to $23.83 by 1:01 p.m. ET after President Trump announced “Project Vault,” a $12 billion U.S. plan to stockpile critical minerals. The U.S. Export-Import Bank approved up to $10 billion in direct loans for the effort. Investors also lifted MP Materials and USA Rare Earth. A ministerial on critical minerals is set for Feb. 4 in Washington.
3 February 2026
······
Denison Mines stock drops 4% as uranium shares slide on fresh supply news — what to watch next

Denison Mines stock drops 4% as uranium shares slide on fresh supply news — what to watch next

Denison Mines shares dropped 4.4% to $3.78 early Tuesday in New York, tracking declines across uranium stocks after Uzbekistan announced higher production and new mines. UxC Uranium futures hovered near $99 per pound. Denison awaits Canadian federal approvals to begin construction at its Phoenix ISR mine, targeting a mid-2028 production start if permits arrive this quarter.
3 February 2026
·····
Centrus Energy (LEU) stock price jumps into long weekend as nuclear fuel trade stays in focus

Centrus Energy (LEU) stock price jumps into long weekend as nuclear fuel trade stays in focus

Centrus Energy shares surged 8.2% to $331.03 Friday, with trading volume near 1.6 million, after the U.S. signed a civil nuclear deal with Slovakia and investors focused on government-backed reactor plans. Cameco rose 3.2%, BWX Technologies 2.2%, and NuScale Power 7.0%. Centrus recently secured a $900 million Department of Energy contract to expand uranium enrichment in Ohio. U.S. markets reopen Tuesday.
17 January 2026
······
NuScale Power stock jumps as Washington’s AI power plan puts new reactors back in play

NuScale Power stock jumps as Washington’s AI power plan puts new reactors back in play

NuScale Power shares climbed about 6% to $20.03 by midday Friday, leading U.S. power stocks after White House efforts to shift more grid costs to data center operators. PJM grid states prepared to sign a two-year price cap deal at the White House, sources said. Traders watched for possible PJM auction changes affecting nuclear project economics. Volume in NuScale topped 20 million shares by early afternoon.
16 January 2026
·······
Denison Mines stock jumps with uranium names as Phoenix approvals come into focus

Denison Mines stock jumps with uranium names as Phoenix approvals come into focus

Denison Mines shares rose about 4.1% to $3.70 Friday morning, trading as high as $3.80, as uranium stocks advanced. Cameco gained 3.8% and Uranium Energy jumped 4.6%. Investors are watching for final approvals on Denison’s Phoenix uranium mine in Canada, which could start construction this year. Around 7.3 million Denison shares changed hands by mid-morning.
16 January 2026
·····
Oklo stock jumps toward $100 as DOE’s $2.7 billion uranium move lifts nuclear plays

Oklo stock jumps toward $100 as DOE’s $2.7 billion uranium move lifts nuclear plays

Oklo Inc. shares climbed 7% to $95.60 in after-hours trading Tuesday after the U.S. Department of Energy awarded $2.7 billion in enrichment contracts to boost domestic nuclear fuel supply. The stock hit $96.82 earlier, with 20 million shares traded. Other nuclear-linked stocks, including NuScale Power and Centrus Energy, also advanced. The DOE awards do not fund Oklo’s reactor construction.
7 January 2026
····
Oklo stock jumps nearly 15% as DOE backs uranium enrichment — what’s next for OKLO

Oklo stock jumps nearly 15% as DOE backs uranium enrichment — what’s next for OKLO

Oklo shares jumped 14.8% to $89.34 Monday, tracking gains across nuclear-linked stocks after the U.S. Energy Department announced $2.7 billion in uranium-enrichment contracts. The awards aim to boost domestic supply of high-assay low-enriched uranium, a key fuel for advanced reactors. Oklo’s after-hours trading was flat. Traders are watching for further federal fuel awards and Friday’s U.S. jobs data.
6 January 2026
····
Cameco Stock (CCJ) Weekend Update: Unusual Options Activity, Uranium Price Backdrop, and Analyst Targets Ahead of Monday’s Open

Cameco Stock (CCJ) Weekend Update: Unusual Options Activity, Uranium Price Backdrop, and Analyst Targets Ahead of Monday’s Open

Cameco (NYSE: CCJ) closed Friday at $92.84, down $0.50, with Toronto shares at C$127.48. Unusual options activity saw put volume surge to 28,210 contracts, up 942% from average, according to MarketBeat. Uranium prices hovered near $81.40 per pound on Dec. 26, supporting sector sentiment. U.S. markets resume trading Monday.
27 December 2025
··
Cameco Stock (CCJ) Outlook on December 10, 2025: Can the Uranium Leader Sustain Its Nuclear and AI-Fueled Rally?

Cameco Stock (CCJ) Outlook on December 10, 2025: Can the Uranium Leader Sustain Its Nuclear and AI-Fueled Rally?

Cameco shares closed at $90.64 in New York on December 10, down for the day but up about 80% year-to-date and over 300% in four years. The uranium producer’s market cap stands near $41 billion, with a P/E above 100. Recent 13F filings show Intact and Guggenheim increasing stakes, while Ossiam and XTX Topco cut positions. Shares remain about 15% below their 52-week high.
10 December 2025
···
Trump’s $80B Nuclear Power Shock: The Future of Energy and AI

Trump’s $80B Nuclear Power Shock: The Future of Energy and AI

The U.S. government reached an $80 billion deal with Brookfield and Cameco to build new nuclear reactors, announced Oct. 28 during President Trump’s Asia trip. Japan pledged up to $332 billion for U.S. infrastructure, including Westinghouse AP1000 reactors. Cameco shares surged up to 25% on the news. The government will arrange financing and permits in exchange for a 20% profit share and possible equity stake.
29 October 2025
····
Cameco Stock Rockets on $80B US Nuclear Reactor Deal — Is the Uranium Bull Market Here to Stay?

Cameco Stock Rockets on $80B US Nuclear Reactor Deal — Is the Uranium Bull Market Here to Stay?

Cameco and Brookfield announced an $80 billion U.S.-backed deal to build new Westinghouse nuclear reactors. CCJ shares jumped 10–15% on the news, extending a rally that has lifted the stock up 65–80% year-to-date. Uranium prices remain near multi-year highs as supply tightens and global pro-nuclear policies accelerate new projects. Wall Street analysts maintain a consensus “Buy” rating on Cameco.
28 October 2025
·
1 2

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop